Consumer-led care is shocking the system.
Exposed
As perception of US healthcare quality drops and ACA premiums double, satisfaction has hit record lows, and insurance enrollment is declining. Losing trust, 69% of citizens believe hospitals care more about making money than serving patients.
Opting out of insurance, more people are patchworking care via DTC platforms, grey market prescriptions, medical tourism, and concierge longevity clinics.
Wartime
Opportunistic or altruistic, consumer-facing providers are going rogue, sparking an all-out war for ownership of the next-gen customer funnel.
Hims vs FDA. Undercutting Novo Nordisk’s $150 oral Wegovy, Hims announced a $49/mo. compounded—and unproven—GLP-1 pill last week. A line crossed, the FDA stepped in, and Novo filed suit. Hims retracted the product but called the response an assault on consumer access.
FDA vs. Novo. Catching its own regulatory flak, the drugmaker received an FDA warning for ads falsely insinuating its pill’s benefits extend to emotional and psychological relief.
Function vs. Superpower. Challenging its primary competitor, Function Health filed a false advertising suit against Superpower, alleging its lab testing capabilities are embellished.
TrumpRx vs. PBMs. Blaming Big Pharma for drug price-gouging, the government’s new cost comparison site aggregates negotiated purchase options for cash-pay customers.
OpenAI vs. Anthropic. With AI reshaping the industry, both tech companies recently debuted healthcare products. Battling for brand trust, Anthropic’s Super Bowl spot trolled OpenAI for integrating ads, eliciting a response from Sam Altman.
Workarounds. Removing insurance friction, Lotus Health AI just raised $35M to offer free primary care by employing a sponsorship-based revenue model. Meanwhile, Solace Health scored $130M for advocacy-as-a-service, highlighting the rising value of coordination.
Looking ahead: DIY care must prove it’s as credible as convenient. AI, telehealth, and consumer platforms are accelerating access, personalization, and price transparency — but without shared accountability, the new system risks repeating old patterns.
